TITLE

FDA Actions

PUB. DATE
February 2011
SOURCE
Internal Medicine Alert;Mar2011 Pharmacology Watch, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of Food and Drug Administration (FDA) to use vilazodone hydrochloride to treat patients with depression.
ACCESSION #
59994112

 

Related Articles

  • Serzone approved by the FDA.  // Drug Topics;1/23/95, Vol. 139 Issue 2, p8 

    Reports that nefazodone has been granted a US Food & Drug Administration approval for the treatment of depression.

  • FDA Actions. Elliott, William T. // Neurology Alert;Mar2011 Primary Care, p2 

    The article presents updates on the actions of the U.S. Food and Drug Administration (FDA) as of March 2011, including its approval of vilazodone hydrocholoride for the treatment of depression in adults, its move to limit the amount of acetaminophen in combination prescription pain medications,...

  • FDA Actions.  // OB/GYN Clinical Alert;Mar2011 Pharmacology, p2 

    The article reports on the decision of the U.S. Food and Drug Administration (FDA) to approve vilazodone hydrochloride for the treatment of depression in adults.

  • Seroquel XR OK'd for MDD.  // Monthly Prescribing Reference;Jan2010, Vol. 26 Issue 1, pA11 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the drug Seroquel XR from AstraZeneca PLC as adjunctive treatment to antidepressants in adults with major depressive disorder (MDD).

  • FDA: Do Not Use Paxil To Treat Pediatric Depression.  // RN;Aug2003, Vol. 66 Issue 8, p93 

    Recommends that paroxetine HCl should not be used to treat depression in children and teenagers under age 18, according to the U.S. Food and Drug Administration.

  • Phenylpiperazine antidepressant.  // Modern Medicine;Feb95, Vol. 63 Issue 2, p31 

    Reports on the approval of the drug Nefazodone HCL by the US Food and Drug Administration (FDA) for treating depression. Duration of the drug's efficacy; Need for physicians to reevaluate the drug's effectiveness; Contraindications.

  • Eli Lilly: Cymbalta approved for treatment of anxiety.  // PharmaWatch: CNS;Apr2007, Vol. 6 Issue 4, p9 

    The article reports on the approval of Eli Lilly's Cymbalta, a serotonin and norepinephrine reuptake inhibitor for the treatment of patients with generalized anxiety disorder (GAD), by the U.S. Food and Drug Administration. Cymbalta is a class of drugs that is primarily indicated for the...

  • A review of novel agents added to the pharmaceutical armamentarium.  // Formulary;Dec2003, Vol. 38 Issue 12, p674 

    This article presents information related to the use of various pharmaceutical drugs in the treatment of different diseases. Many anti-depressant drugs are available in the U.S. to treat depression. Duloxetine is a reuptake inhibitor at serotonergic and noradrenergic neurons and appears to have...

  • New molecular entities.  // Formulary;Sep2004, Vol. 39 Issue 9, p428 

    Reports on the United States Food and Drug Administration's approval of antidepressant Duloxetine for the treatment of major depressive disorder. Efficacy; Safety; Dosing.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics